• Profile
Close

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer: An exploratory analysis of the Intergroup trial AGO-OVAR 12

Gynecologic Oncology Feb 02, 2019

Heitz F, et al. - Authors assessed 1,345 patients with advanced ovarian cancer (AOC) to find contributing factors for impaired survival in cases with completely resected AOC. They observed tumor in 28% and 22% of those undergoing radiologic and integrated assessment, respectively. They also noted 5-year overall survival (5Y-OS) of 72% and 71% among those with surgical- radiological and surgical-integrated concordant findings. An inferior 5Y-OS of 47% and 49% was also recorded for candidates with surgical-radiological and surgical-integrated discordant results. They noticed that cases with surgically assessed residual disease had a 5-YOS of 37%. An independent relationship was observed between the interval between surgery and baseline assessment and discordance between assessment methods, which might reflect early tumor regrowth.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay